

Literaturverzeichnis

- [1] Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. *J Rheumatol* 22: 1259-1264 (1995)
- [2] Anaya JM, McGuff S, Banks PM., Talal N : Clinicopathological factors relating malignant lymphoma with Sjögren´s syndrome. *Semin Arthritis Rheum* 25: 337-346 (1996)
- [3] Andrys C, Krejsek J, Slezak R, Drahosova M, Kopecky O: Serum soluble adhesion molecules (sICAM-1, sVCAM-1, sE-Selectin) and neopterin in patients with Sjögren´s syndrome. *Acta Medica* 42: 97-101 (1999)
- [4] Aziz KE, McCluskey PJ, Wakefield D: Expression of Selectins (CD62 E,L,P) and Cellular Adhesion Molecules in Primary Sjögren´s Syndrome: Questions of Immunoregulation. *Clin. Immunol Immunopathol* 80: 55-66 (1996)
- [5] Baraczka K, Nekam K, Pozsonyi T, Jakab L, Szongoth M, Sesztak M: Concentration of Soluble Adhesion Molecules (sVCAM-1, sICAM-1 and sL-Selectin) in the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis and Systemic Lupus erythematosus with Central Nervous Involvement. *Neuroimmunomodulation* 9: 49-54 (2001)
- [6] Baraczka K, Pozsonyi T, Szongoth M, Nekam K, Megyeri A, Balongh Z, Jakab L: A study of increased levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) in the cerebrospinal fluid of patients with multiple sclerosis and systemic lupus erythematosus. *Acta Neurol Scand* 99: 95-99 (1999)
- [7] Bazil V, Strominger JL: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. *J Immunol* 147: 1567-1574 (1991)
- [8] Beebe AM, Cua DJ, de Waal Malefyt R: The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). *Cytokine Growth Factor Rev* 13: 403-412 (2002)
- [9] Belmont HM, Hopkins P, Edelson HS: Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate during exacerbations of disease. *Arthritis Rheum* 29: 1985-1989 (1986)
- [10] Bertsch T, Richter A: Cytokines and Soluble Adhesion Molecules in Laboratory Diagnostics. *Clin Chem Med* 36: 409-413 (1998)
- [11] Bevilacqua MP, Stengelein S, Gimbrone MA, Seed B: Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor für Neutrophils Related to Complement Regulatory Proteins and Lectins. *Science* 243: 1160-1164 (1998)
- [12] Blondin C, Le Dur A, Cholley B, Caroff M, Haeffner-Cavaillon N : Lipopolysaccharide complexed with soluble CD14 binds to normal human monocytes. *Eur J Immunol* 27: 3303-3309 (1997)
- [13] Boehme MWJ, Reath U, Galle PR, Stremmel, W, Scherbaum WA: Serum thrombomodulin- a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. *Clin Exp Immunol* 119: 189-195 (2000)
- [14] Buckley CD, Simmons DL: Cell adhesion: a new target for therapy. *Mol Med today*: 449-456 (1997)

- [15] Bunim JJ, Talal N: The assoziation of malignant lymphoma in the course of Sjögren´s syndrome. *Trans Assoc Am Phycicians* 76: 45-56 (1963)
- [16] Carson CW, Beall LD, Hunder GG, Johnson CM, Newman,W: Serum ELAM-1 is increased in Vasculitis, Scleroderma and Systemic Lupus Erythematosus. *J Rheumatol* 20: 809-814 (1993)
- [17] Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J: Circulating Activated Endothelial Cells in Systemic Lupus Erythematosus. *Arthritis Rheumat* 44: 1203-1208 (2001)
- [18] Constantopoulos SH, Tsianos EV, Moutsopoulos HM: Pulmonary and gastrointestinal manifestations of Sjögren´s syndrome. *Rheum Dis Clin North Am*18: 617-635 (1992)
- [19] Cowley HC, Heney D, Gearing AJH, Hemingway I, Webster NR: Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: A prospective cohort study. *Crit Care Med* Vol. 22: 651-657 (1994)
- [20] Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. *Clin Pharmacokinet* 44: 61-98 (2005)
- [21] Daniel L, Sichez H, Giorgi R, Dussol B, Figarelle-Branger D, Pellissier JF, Berland Y: Tubular lesions and tubular cell adhesion molecules for the prognostics of lupus nephritis. *Kidney Int* 60: 2215-2221 (2001)
- [22] Diaz-Gonzalez F, Sanches-Madrid F: Inhibition of leucocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs. *Immunol Today* 19: 169-172 (1998)
- [23] Dehinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR: Intestinal lung disease in primary Sjögren´s syndrome. Clinical-pathological evaluation and response to treatment. *Am J Respir Crit Care Med* 154: 794-799 (1996)
- [24] Di Lorenzo G, Pacor ML, Mansueto P, Lo Bianco C, Di Natale E, Rapisarda F, Pellitteri ME, Ditta V, Gioe A, Giammarresi G, Rini GB, Vecchi M: Circulating levels of soluble adhesion molecules in patients with ANCA-associated vasculitis. *J Nephrol* 17: 800-7 (2004)
- [25] Dougherty GJ, Murdoch S, Hogg N: The function of humen intercellular adhesion molecule-1 (Icam-1) in the generation of an immune response. *Eur J Immunol* 18: 35-39 (1988)
- [26] Drosos AA, Andonopopoulos AP, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM: Prevalencs of primary Sjögren´s syndrome in an elderly population. *Br J Rheumatol* 27: 123-127 (1988)
- [27] Dujvestijn A, Hamann A: Mechanisms and regulation of lymphocyte migration. *Immunol Today* 10: 23-28 (1989)
- [28] Egerer K, Hertzler J, Feist E, Albrecht A, Rudolph PE, Dörner T, Burmester G-R: sE-Selectin for Stratifying Outcome in Rheumatoid Arthritis. *Arthritis Rheum (Arthritis Care Res)* 49: 546-548 (2003)
- [29] Egerer K, Feist E, Rohr U, Pruß A, Burmester G-R, Dörner T: Increased serum soluble CD14, ICAM-1 and E-Selectin correlates with disease activity and prognosis in systemic lupus erythematosus. *Lupus* 9: 1-8 (2000)
- [30] Engelmann L, Kornhuber B, Rommelsheim K, Vogt S (Hrsg.): Endotoxin, Infektion, Sepsis. *Clin Immunol* 4: 12-37 (1995)

- [31] Flescher E, Talal N: Do viruses contribute to the development of Sjögren`s syndrome. *Am J Med* 90: 283-285 (1991)
- [32] Fox RI, Pearson G, Vaughan JH: Detection of EBV associated antigen and DNA in salivary gland biopsies of Sjögren´s syndrome. *J Immunol* 137: 3162-3168 (1985)
- [33] Fries J, Williams WU, Amy J, Atkins RC, Newman W, Collins T: Expression of Vcam-1 and E-Selectin in an *in Vivo* Model of Endothelial Activation. *Am J Pathol* 143: 725-737 (1993)
- [34] Gladman DD, Urowitz MB: Systemic lupus erythematosus. Clinical Features. In Klippel J.H., P.A. Dieppe: *Rheumatology*. Mosby, St. Louis 6.2.1.-6.2.20 (1994)
- [35] Gottsauer-Wolf M, Sochor H, Probst P, Rödler S, Balcke P, Stockenhuber F: Preliminary data of sIcam-1 in patients with acute myocardial infarction, *Wien Med Wochenschr* 142: 7 (1992)
- [36] Hahn BH: Systemischer Lupus erythematosus. in Schmailzl Kurt JG (Hrsg.): *Harrisons Innere Medizin Teil 2*, 13. Auflage, Blackwell Wissenschaftsverlag 1995, 1915- 1921
- [37] Harley JB, Reichlin M, Arnett FC, Alexander EL, Bias WB, Provost TT: gene interaction at HLA DQ enhances autiantibody production in primary Sjögren´s syndrom. *Science* 232: 1145-1147 (1988)
- [38] Herold M, Mur E: sIcam-1 levels in patients with rheumatoid arthritis, *Wien Med Wochenschr* 142: 7 (1992)
- [39] Hiepe F, Riemekasten G, Dörner T: Autoantikörperdiagnostik beim systemischen Lupus erythematosus (SLE). *Akt Rheumatol* 21: 62-71 (1996)
- [40] Hiki N, Berger D, Dentener MA, Mimura Y, Buurman WA, Prigl C, Seidelmann M, Tsuji E, Kaminishi M, Beger HG: Changes in Endotoxin-Binding Proteins during Major Elective Surgery: Important Role of Soluble CD14 in Regulation of Biological Activity of Systemic Endotoxin. *Clin Diagn Lab Immunol* 6: 844-850 (1999)
- [41] Hiki N, Berger D, Prigl C, Boelke E, Wiedeck H, Seidelmann M, Staib L, Kaminishi M, Oohara T, Beger HG: Endotoxin Binding and Elimination by Monocytes: Secretion of Soluble CD14 Represents an Inducible Mechanism Counteracting Reduced Expression of Membrane CD14 in Patients with Sepsis and in Patient with Paroxysmal Nocturnal Hemoglobinurie. *Infect Immun* 66: 1135-1141 (1998)
- [42] Ho CY, Wong CK, Li EK, Tam LS, Lam CW: Elevated plasma concentrations of nitric oxide, soluble thrombomodulin und soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus, *Rheumatology* 52: 117-122 (2003)
- [43] Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 40: 1725 (1997)
- [44] Horak P, Scudla V, Hermanova Z, Pospisil Z, Faltynek L, Budikova M, Kusa L: Clinical Utility of Selected Disease Activity Markers in Patients with systemic lupus erythematosus. *Clin Rheumatol* 20: 337-344 (2001)
- [45] Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K: Relationship between lupus activity and the serum level if soluble VCAM-1. *Lupus* 7: 347-354 (1998)

- [46] Jacobsson LT, Axell TE, Hansen BU, Henricsson VJ, Larsson A, Lieberkind K, Lilja B, Manthorpe R: Dry eyes or mouth-an epidemiological study in Swedish adults, with special reference to primary Sjögren's syndrome. *J Autoimmun* 2: 521-527 (1989)
- [47] Janssen BA, Luqmani RA, Gordon C, Hemingway IH, Bacon PA, Gearing AJ, Emery P: Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. *Br J Rheumatol* 33: 1112-1116 (1994)
- [48] Jones SK: The effects of hormonal and other stimuli on cell surface Ro/SSA antigen expression by human keratinocytes in vitro: their possible role in the induction of cutaneous lupus lesions. *Br J Dermatol* 126: 554-560 (1992)
- [49] Kaplan JG, Rosenberg R, Reinitz E, Buchbinder S, Schaumburg HH: Peripheral neuropathy in Sjögren's syndrome. *Muscle Nerve* 13: 570-579 (1990)
- [50] Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, Durand J-M, Harle J-R, Bongrand P, Piette J-C: Increased soluble Vascular Cell Adhesion Molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome. *Arthritis Rheum* 43: 55-64 (2000)
- [51] Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberley RP, Budman DR, Costa J, Decker JL, Chused TM: Increased risk of lymphoma in sicca syndrome. *Ann Intern Med* 89: 888-892 (1978)
- [52] Kerr LD, Adelsberg BR, Spiera H: Complement activation in systemic lupus erythematosus: a marker of inflammation. *J Rheumatol* 13: 313-319 (1986)
- [53] Kevil CG, Bullard DC: Roles of Leukocyte/ Endothelial Cell Adhesion Molecules in the Pathogenesis of Vasculitis. *Am J Med* 106: 677-687 (1999)
- [53a] Keyßer G, Kamradt Th, Burmester G-R: Struktur und Funktion des zellulären und humeralen Immunsystems. in Miehle W, Fehr K, Schattenkirchner M, Tillmann K (Hrsg.): *Rheumatologie in Klinik und Praxis*, 2. völlig neu bearbeitete Auflage, Georg Thieme-Verlag 2000, 39- 48
- [54] Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J: Soluble adhesion molecules (ICAM-1, VCAM-1, and E-Selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. *Ann Rheum Dis* 61: 804-809 (2002)
- [55] Kling E, Bieg S, Boehme M, Scherbaum WA: Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. *Clin Investig* 71: 299-304 (1993)
- [56] Kubes P: Introduction: The complexities of leukocyte recruitment, *Semin Immunol* 14: 65-72 (2002)
- [57] Landmann R, Link S, Sansano S, Rajacic Z, Zimmerli W: Soluble CD14 Activates Monocytic Cells Independently of Lipopolysaccharide. *Infect Immun* 66: 2264-2271 (1998)
- [58] Lange K, Ores R, Strauss W, Wachstein M: Steroid therapy of systemic lupus erythematosus based on immunologic considerations. *Arthritis Rheum* 8: 244-259 (1964)
- [59] Lai KN, Leung JCK, Lai KB, Wong KC, Lai CKW: Upregulation of Adhesion Molecule Expression on Endothelial Cells by Anti-DNA Antibodies in Systemic Lupus Erythematosus. *Clin Immunol Immunopathol* 81: 229-238 (1996)

- [60] Lhotta K, Neumayer HP, Joannidis M, Geissler D, König P: Renal expression of Icam-1 in different forms of glomerulonephritis. *Wien Med Wochenschr* 142: 6 (1992)
- [61] Lisby S, Ralfkiaer E, Rothlein R, Vejlsgaard GL: Intercellular adhesion molecule-1 (ICAM-1) expression correlated to inflammation. *Br J Dermatol* 120: 479-484 (1989)
- [62] Lloyd W, Schur PH: Immune complexes, complement and anti-DNA in exacerbations of systemic lupus erythematosus. *Medicine* 60: 208-217 (1981)
- [63] Mally M, Schaudt M: Adhäsionsmoleküle steuern die Kommunikation der Zellen. *Lab Med* 15: 391 (1991)
- [64] Marlin SD, Springer TA: Purified Intercellular Adhesion Molecule-1 (ICAM-1) Is a Ligand for Lymphocyte Function-Associated Antigen 1 (LFA-1). *Cell* 51: 813-819 (1987)
- [65] Marlin SD: sIcam-1: A soluble receptor antagonist of rhinovirus binding. *Wien Med Wochenschr* 142: 3 (1992)
- [66] Mathison JC, Wright SD, Ramos RA, Tobias PS, Ulevitch RJ : CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science* 249: 1431-3 (1990)
- [67] Martin S, Rieckmann P, Melchers I, Wagner R, Bertrams J, Voskuyl AE, Roep BO, Zielasek J, Heidenthal E, Weichselbraun I, Gallatin WM, Kolb H: Circulating forms of Icam-3 (cICAM-3). *J Immunol* 154: 1951-1955 (1995)
- [68] Minter MF, Stollar BD, Agnello V: Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus. *Arthritis Rheum* 22: 959-968 (1979)
- [69] Mosevold KA, Bruserud O: Circadian variations do not have a major impact on serum levels of soluble (s) L-Selectin (CD63L), s-intercellular adhesion molecule 1 (sICAM-1/CD54) and thrombopoietin in healthy individuals. *Scand J Clin Lab Invest* 62 : 75-80 (2002)
- [70] Moutsopoulos HM: Sjögren-Syndrom. in Schmailzl Kurt JG (Hrsg.): *Harrisons Innere Medizin Teil 2*, 13. Auflage, Blackwell Wissenschaftsverlag 1995, 1938-1940
- [71] Mrowka Ch, Sieberth HG: Detection of circulating adhesion molecules ICAM-1, VCAM-1 and E-Selectin in Wegener's granulomatosis, systemic lupus erythematosus und chronic renal failure. *Clin Nephrol* 43: 288-296 (1995)
- [72] Nagahama M, Nomura S, Ozaki Y, Yoshimura C, Kagawa H, Fukuhara S: Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. *Autoimmunity* 33: 85-94 (2001)
- [73] Nakatani K, Fujii H, Hasegawa H, Terada M, Arita N, Ito MR, Ono M, Takahashi S, Saiga K, Yoshimoto S, Iwano M, Shiiki H, Saito Y, Nose M : Endothelial adhesion molecules in glomerular lesions : association with their severity and diversity in lupus models. *Kidney Int* 65 : 1290-300 (2004)
- [74] Nockher WA, Wigand R, Schoeppe W, Scherberich JE: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. *Clin Exp Immunol* 96: 15-19 (1994)
- [75] Osborn L: Leukocyte adhesion to endothelium inflammation. *Cell* 62: 3-6 (1990)

- [76] Osborn L, Hession C, Tizard R, Vassallo C, Lühowskyj S, Chi-Rosso G, Lobb R: Direct Expression Cloning of Vascular Cell Adhesion Molecule 1, a Cytokine-Induced Endothelial Protein That Binds to Lymphocytes. *Cell* 59: 1203-1211 (1989)
- [77] Patarroyo, M, Malegapuru MW: Leucocyte adhesion to cells in immune and inflammatory responses. *Lancet* 11: 1139-1141 (1989)
- [78] Patel KD, Cuvelier SL, Wiehler S: Selectins : critical mediators of leukocyte recruitment. *Semin Immunol* 14: 73-81 (2002)
- [79] Pober JS : Endothelial activation : intracellular signaling pathways. *Arthritis Res* 4 (Supp.): 109-116 (2002)
- [80] Pober JS, Cotran RS: The Role of Endothelial cells in inflammation, *Transplantation* 50: 537-544 (1990)
- [81] Popp W, Fucik E, Kramer G, Hainz R, Rami B, Böck A, Herkner K, Zwick H, Sertl K: Icam-1 in pulmonary health and bronchial hyperresponsiveness, *Wien Med Wochenschr* 142 (1992) No. 4, 7
- [82] Redl H, Schlag G, Dinges HP, Buurman WA: ELAM-1 expression in experimental septicemia. *Wien Med Wochenschr* 142 (1992) No. 4, 6
- [83] Rokita E, Menzel EJ: Characteristics of CD14 shedding from human monocytes. *APMIS* 105: 510-518 (1997)
- [84] Rothlein R, Mainolfi EA, Czaikowski M, Marlin SD: A form of circulating Icam-1 in human serum. *J Immunol* 147: 3788-3793 (1991)
- [85] Rothlein R, Mainolfi E, Marlin S: Identification and characterization of a circulating form of Icam-1 in human sera. *Wien Med Wochenschr* 142: 3 (1992)
- [86] Russel AI, Graham DS, Chadha S, Robertson C, Fernandez-Hart T, Griffiths B, D´Cruz D, Nitsch D, Whittaker JC, Vyse TJ: No association between E- and L-selectin genes and SLE: soluble L-selectin levels do correlate with genotype and a subset in SLE. *Genes Immun* 19: 1466
- [87] Sari RA, Taysi S, Erdem F, Yilmaz O, Keles S, Kiziltunc A, Obadas A, Cetinkaya R: Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus. *Rheumatol Int* 21: 149-152 (2002)
- [88] Scherberich JE, Nockher WA: CD14⁺⁺Monocytes, CD14⁺/CD16⁺Subset and soluble CD14 as Biological Markers of Inflammatory Systemic Diseases and Monitoring Immunosuppressive Therapy. *Clin Chem Lab Med* 37: 209-213 (1999)
- [89] Schütt C, Schumann R: Der Endotoxinrezeptor CD14. *Immun Infect* 21: 36-40 (1993)
- [90] Seth R, Raymond FD, Makgoba MW: Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. *Lancet* 338: 83-84 (1991)
- [91] Shimizu Y, Newman W, Tanaka Y, Shaw S: Lymphocyte interactions with endothelial cells. *Immunol Today* 13: 106-112 (1992)
- [92] Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ: Anti-dsDNA: choice of assay in relation to clinical value. *Rheumatol Int* 11: 101-107 (1991)

- [93] Späth M, Krüger K: Sjögren Syndrom. in Miehle W, Fehr K, Schattenkirchner M, Tillmann K (Hrsg.): Rheumatologie in Klinik und Praxis, 2. völlig neu bearbeitete Auflage, Georg Thieme-Verlag 2000, 1042- 1056
- [94] Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CGM: Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-Selectin during disease exacerbation in patients with systemic lupus erythematosus (SLE); a long term prospective study. *Clin Exp Immunol* 97: 439-444 (1994)
- [95] Spronk PE, Limburg PC: Serological markers of disease activity in systemic lupus erythematosus. *Lupus* 4: 86-94 (1995)
- [96] Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA: Primary Structure of Icam-1 Demonstrates Interaction between Members of the Immunoglobulin and Integrin Supergene Families. *Cell* 52: 925-933 (1988)
- [97] Stockenhuber F, Gnant M, Götzinger P, Wamser P, Steininger R, Schenn G, Mühlbacher F, Balcke P: Soluble Icam-1 in renal and liver transplant recipients. *Wien Med Wochenschr* 142: 6 (1992)
- [98] Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 25 (1982)
- [99] Thomas L [Hrsg.]: Labor und Diagnose., 4. Auflage – Med. Verlagsgesellschaft Marburg (1995), 990-1005
- [100] Tulek N, Aydintug O, Ozoran K, Tutkak H, Duzgun N, Duman M: Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus. *Clin Rheumatol* 1: 47-50 (1996)
- [101] Turkcapar N, Sak SD, Saatci M, Duman M, Olmez U: Vasculitis and Expression of Vascular Cell Adhesion Molecule-1, Intercellular Adhesion Molecule-1, and E-Selectin in Salivary Glands of Patients with Sjogren´s Syndrome. *J Rheumatol* 32: 1063-70 (2005)
- [102] Venables PJ, Rigby SP: Viruses in the etiopathogenesis of Sjögren`s syndrome. *J Rheumatol* 50: 3-5 (1997)
- [103] Veszy CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS: Lipopolysaccharide-Binding Protein and Phospholipid Transfer Protein Release Lipopolysaccharides from Gram-Negative Bacterial Membranes. *Infect Immun* 68: 2410-2417 (2000)
- [104] Vitali C, Bencivelli W, Isenberg DA: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. *Clin Exp Rheumatol* 10: 527-39 (1992)
- [105] Vitali C, Bombardieri S, Moutsopoulos HM: Preliminary criteria for the classification of Sjögren`s syndrome. *Arthritis Rheum.* 36: 340-346 (1993)
- [105a] Vitali, C, Bombardieri, S, Jonsson, R, Moutsopoulos, HM, et al.: Classification criteria for Sjogren´s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann. Rheum. Dis.* 61(6): 554-8 (2002)
- [106] Wais T, Fierz W, Stoll T, Villiger PM: Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. *J Rheumatol* 10: 2133-2139 (2003)

- [107] Welicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO: Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. *Clin Exp Immunol* 92: 412-418 (1993)
- [108] Williams AF, Barclay AN: The immunoglobulin superfamily- domains for cell surface recognition: *Ann Rev Immunol* 6: 381-405 (1988)
- [109] Winfield JB, Faiferman I, Koffler D: Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. *J Clin Invest* 59: 90-6 (1977)
- [110] Witkowska AM, Borawska MH: Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. *Eur Cytokine Netw* 15: 91-8 (2004)
- [111] Wuthrich RP, Jevnikar AM, Takei FL, Glimcher H, Kelley VE: Intercellular Adhesion Molecule-1 (ICAM-1) Expression is Upregulated in Autoimmune Murine Lupus Nephritis. *Am J Pathol* 136: 441-450 (1990)
- [112] Yokoyama H, Takaeda M, Wada T, Ohta S, Hisada Y, Segawa C, Furuichi K, Kobayashi K: Glomerular Icam-1 Expression Related to Circulating TNF- α in Human Glomerulonephritis. *Nephron* 76: 425-433 (1997)
- [113] Yoshikawa H, Nakajima Y, Tasaka K: Glucocorticoid Suppresses Autocrine Survival of Mast Cells by Inhibiting IL-4 Production and ICAM-1 Expression. *J Immunol* 162: 6162-6170 (1999)
- [114] Ziegler-Heitbrock HWL, Ulevitch RJ: CD14: Cell surface receptor and differentiation marker. *Immunol today* 14: 121-125 (1993)